Agomab Therapeutics prices 200 million dollars Nasdaq IPO
Agomab Therapeutics has priced its initial public offering at 16 dollars per American Depositary Share (ADS), raising expected gross proceeds of approximately 200 million dollars before underwriting discounts and expenses.


